BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morgner A, Labenz J, Miehlke S. Effective regimens for the treatment of Helicobacter pylori infection. Expert Opin Investig Drugs 2006;15:995-1016. [PMID: 16916269 DOI: 10.1517/13543784.15.9.995] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56:1353-1357. [PMID: 17566020 DOI: 10.1038/gut.2007.125658] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Sasaki N, Matsumoto T, Ikenaka Y, Kazusaka A, Ishizuka M, Fujita S. Furazolidone induces the activity of microsomal enzymes that metabolize furazolidone in chickens. Pesticide Biochemistry and Physiology 2011;100:135-9. [DOI: 10.1016/j.pestbp.2011.02.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Kuo CH, Hsu PI, Kuo FC, Wang SS, Hu HM, Liu CJ, Chuah SK, Chen YH, Hsieh MC, Wu DC. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. J Antimicrob Chemother. 2013;68:222-228. [PMID: 22984204 DOI: 10.1093/jac/dks361] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
4 Kuo CH, Wang SS, Hsu WH, Kuo FC, Weng BC, Li CJ, Hsu PI, Chen A, Hung WC, Yang YC. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter. 2010;15:265-272. [PMID: 20633187 DOI: 10.1111/j.1523-5378.2010.00761.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
5 Morgner A, Schmelz R, Thiede C, Stolte M, Miehlke S. Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol 2007; 13(26): 3554-3566 [PMID: 17659705 DOI: 10.3748/wjg.v13.i26.3554] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
6 Furuta T, Sugimoto M, Shirai N, Matsushita F, Nakajima H, Kumagai J, Senoo K, Kodaira C, Nishino M, Yamade M. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment Pharmacol Ther. 2007;26:693-703. [PMID: 17697203 DOI: 10.1111/j.1365-2036.2007.03408.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
7 Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56:1353-1357. [PMID: 17566020 DOI: 10.1136/gut.2007.125658] [Cited by in Crossref: 201] [Cited by in F6Publishing: 185] [Article Influence: 13.4] [Reference Citation Analysis]
8 Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol. 2009;58:930-935. [PMID: 19502370 DOI: 10.1099/jmm.0.009993-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
9 Wöhrer S, Troch M, Raderer M. Therapy of gastric mucosa-associated lymphoid tissue lymphoma. Expert Opin Pharmacother 2007;8:1263-73. [PMID: 17563261 DOI: 10.1517/14656566.8.9.1263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
10 Miehlke S, Schneider-Brachert W, Kirsch C, Morgner A, Madisch A, Kuhlisch E, Haferland C, Bästlein E, Jebens C, Zekorn C. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2008;13:69-74. [PMID: 18205669 DOI: 10.1111/j.1523-5378.2007.00588.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
11 Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Shirai N, Ikuma M, Hishida A, Ishizaki T. Personalized medicine for eradication of Helicobacter pylori. Per Med 2007;4:321-8. [PMID: 29788670 DOI: 10.2217/17410541.4.3.321] [Reference Citation Analysis]
12 Buzás GM, Józan J. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. J Gastroenterol Hepatol. 2007;22:1571-1581. [PMID: 17845685 DOI: 10.1111/j.1440-1746.2007.05082.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
13 Li M, Li T, Guo S, Liang H, Jiang D. The effect of MDR1 C3435T polymorphism on the eradication rate of H. pylori infection in PPI-based triple therapy: A meta-analysis. Medicine (Baltimore) 2017;96:e6489. [PMID: 28353592 DOI: 10.1097/MD.0000000000006489] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
14 Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis. 2008;60:409-415. [PMID: 18248937 DOI: 10.1016/j.diagmicrobio.2007.11.008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 3.7] [Reference Citation Analysis]
15 Parise RA, Eiseman JL, Clausen DM, Kicielinski KP, Hershberger PA, Egorin MJ, Beumer JH. Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612). Cancer Chemother Pharmacol 2015;76:537-46. [PMID: 26193988 DOI: 10.1007/s00280-015-2828-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]